Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Cartier Silver Outlines an 800m by 500m Epithermal Silver Polymetallic Target on Gonalbert Property, Potosi Department, Southern Bolivia (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Oncolytics Biotech Inc. T.ONC

Alternate Symbol(s):  ONCWF | ONCY

Healthcare Biotechnology
Oncolytics Biotech Inc is a development-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. Its clinical development plan has the approval of its products as quickly as possible and expands its products into commercially valuable new treatment areas as objectives. The company's product pipeline includes Bavencio, Keytruda, Retifanlimab, and Tecentriq.

The Power Play by The Market Herald
{{currentVideo.videoCaption}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous Video {{moreVideoText}} Next Video >

Stock Price Chart (TSX:ONC)

Fundamentals Snapshot (TSX:ONC)

Current News (TSX:ONC)

Oncolytics Biotech® Announces Updated Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial that Show Pelareorep Driving Robust Increases in Progression-Free Survival and Confirmed Overall Response Rate

PR Newswire 3 days ago

Oncolytics Biotech® to Host Key Opinion Leader Webinar on Data from the Randomized BRACELET-1 Trial in HR+/HER2- Metastatic Breast Cancer Being Presented at the Upcoming ASCO Annual Meeting

PR Newswire 12 days ago

New data to be highlighted at the world’s top cancer conference

Jon Brown 12 days ago

Oncolytics Biotech® Announces Positive Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial Demonstrating Pelareorep Drives ≥50% Improvements in ORR and mPFS in an ASCO Annual Meeting Abstract

PR Newswire 13 days ago

Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders

PR Newswire May 10, 2023

Oncolytics Biotech® Reports First Quarter 2023 Financial Results and Operational Highlights

PR Newswire May 5, 2023

Oncolytics Biotech® Announces Upcoming Oral Presentation on Randomized BRACELET-1 Trial in HR+/HER2- Metastatic Breast Cancer at the ASCO Annual Meeting

PR Newswire April 26, 2023

Oncolytics Biotech® to Participate in a Panel Presentation at Canaccord Genuity's Horizons in Oncology Virtual Conference

PR Newswire April 12, 2023

Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights

PR Newswire April 12, 2023
View More News ››

Opinion & Analysis (TSX:ONC)

Buzz on the Bullboards: New Year, New Attractive Stocks

Omri Wallach January 9, 2020

Target Price Raised Ninefold on Biotech After Share Consolidation

Streetwise Reports June 6, 2018

Canadian Biotech comes back to life: A buyer's guide

Tony Pullen January 21, 2014
View More Opinion ››

Bullboard Posts (TSX:ONC)

BIO2023 conference currently in Boston MA.

Ends on June 8, 2023. Most everyone in biotech usually attends with many companies registered as exhibitors or partnering events. Lack of...
Noteable - 10 hours ago

RE:RE:Nice mm raid at the close...

Did he say anything about averaging down way way down?...lol-not 
m00nsh0ts - 13 hours ago

RE:Nice mm raid at the close...

Remember Warren Buffet’s Investing advice......”Buy a good company, and hold”...
Angler101 - 16 hours ago

Nice mm raid at the close...

Obviously somebody put in some stop limits, and now, they’re going to artificially drop the share price and promptly take out the limits...
Angler101 - 16 hours ago

RE:RE:In today's world the paths to FDA Approval are many

Here's a recent example --- June 05, 2023, The FDA has signed off on an amended trial protocol for Theratechnologies’ solid...
Noteable - 18 hours ago

Why KOL was son embarrasing

Expert that worked on Aware-1 basically said in Aware-1 we gave out tylenol that solved dropped out rate. Wow. They did Aware-1 at the...
SundayMovies - 18 hours ago
View more Bullboard ››

Fireweed Metals Corp.

Fireweed Metals Corp.

Fireweed Metals is a Canadian mining exploration and development company focused on advancing the Macmillan Pass and Mactung ...
View More »